EGFR-targeted therapies in colorectal cancer

Diseases of the Colon and Rectum

Volumn 50, Issue 8, 2007, Pages 1259-1270

  Overman, Michael J ^a   Hoff, Paulo M ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HOSPITAL SÍRIO LIBANÊS   (Brazil)

Author keywords

Cetuximab; Colorectal cancer; Combination drug therapy; Epithelial growth factor receptor; Erlotinib; Gefitinib; Panitumumab; Targeted therapy

Indexed keywords

4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; BEVACIZUMAB; CANERTINIB; CAPECITABINE; CETUXIMAB; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LAPATINIB; MATUZUMAB; NALMEFENE; NIMOTUZUMAB; OXALIPLATIN; PANITUMUMAB; PELITINIB; UNCLASSIFIED DRUG; VECTIBIX;

ACNEIFORM RASH; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG INHIBITION; FATIGUE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; NAUSEA; NEUTROPENIA; RASH; SIDE EFFECT; STOMATITIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 34447644730     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/s10350-007-0228-3     Document Type: Article

References (55)

1. RJ Rutman A Cantarow KE Paschkis 1954 Studies in 2-acetylaminofluorene carcinogenesis. II. The in vitro uptake of alanine-1-C14 by preneoplastic liver and hepatoma mitochondrial protein Cancer Res 14 115 118
2. B Vogelstein KW Kinzler 2004 Cancer genes and the pathways they control Nat Med 10 789 799
3. S Yano K Kondo M Yamaguchi 2003 Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition Anticancer Res 23 3639 3650
4. AP Venook 2005 Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma Cancer 103 2435 2446
5. Y Yarden MX Sliwkowski 2001 Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 127 137
6. J Mendelsohn J Baselga 2003 Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J Clin Oncol 21 2787 2799
7. JA McKay LJ Murray S Curran 2002 Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases Eur J Cancer 38 2258 2264
8. D Cunningham Y Humblet S Siena 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337 345
9. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colorectal cancer. Version 2. 2006. 11-15-2005
10. M Moroni S Veronese S Benvenuti 2005 Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study Lancet Oncol 6 279 286
11. Lenz H-J, Mayer RJ, Mirtsching B, et al. Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:255s:3536a
12. Saltz LB, Lenz H, Kindler H, et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:248s:3508a
13. Grothe W, Arnold D, Peinert S, et al. Cetuximab with oxaliplatin and capecitabine (CAPOX) in patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:288s:3669a
14. Rougier P, Raoul JL, Van Laethem JL, et al. Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2005;22:249s:3513a
15. Diaz-Rubio E, Tabernero J, Van Cutsem E, et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:254s:3535a
16. Jennis A, Polikoff J, Mitchell E, et al. Erbitux (cetuximab) plus FOLFOX for colorectal cancer (EXPLORE): preliminary efficacy analysis of a randomized phase III trial. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:265s:3574a
17. Malik I, Hecht JR, Patnaik A, et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:251s:3520a
18. Benson A. Panitumumab, a fully-human IgG2 antibody treatment for colorectal cancer. Paper presented at: The 23rd annual Chemotherapy Foundation Symposium November 2 - 5, 2005, New York, New York [Abstract 4]
19. Peeters M, Van Cutsem E, Siena S, et al. A phase 3, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) vs BSC alone in patients with metastatic colorectal cancer. Paper presented at: American Association of Cancer Research Annual Meeting; April 1, 2006; Washington, DC [Abstract CP-1]
20. U Vanhoefer M Tewes F Rojo 2004 Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor J Clin Oncol 22 175 184
21. Trarbach T, Beyer T, Schleucher N, et al. A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2004;22:199s:3018a
22. ML Rothenberg B LaFleur DE Levy 2005 Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma J Clin Oncol 23 9265 9274
23. HL Kindler G Friberg L Skoog K Wade-Oliver EE Vokes 2005 Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer Am J Clin Oncol 28 340 344
24. ML Veronese W Sun B Giantonio 2005 A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer Br J Cancer 92 1846 1849
25. T Kuo CD Cho J Halsey 2005 Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer J Clin Oncol 23 5613 5619
26. Fisher GA, Kuo T, Cho CD, et al. A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2004;22:248s:3514
27. Zampino MG, Lorizzo K, Massacesi C, et al. First-line gefitinib combined with simplified FOLFOX-6 in patients with epidermal growth factor receptor-positive advanced colorectal cancer. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:285s:3659a
28. Jimeno A, Sevilla I, Gravalos C, et al. Phase I/II trial of capecitabine and gefitinib in patients with advanced colorectal cancer after failure of first-line therapy. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:235s:3176a
29. Oza AM, Townsley CA, Siu LL, et al. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31, 2003; Chicago, Illinois [Abstract 785]
30. Keilholz U, Arnold D, Niederle N, et al. Erlotinib as 2nd and 3rd line monotherapy in patients with metastatic colorectal cancer: results of a multicenter two-cohort phase II trial. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:264s:3575a
31. Meyerhardt JA, Xhu A, Enzinger PC, et al. Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC). J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2005;22:265s:3580a
32. Fields AL, Rinaldi DA, Henderson CA, et al. An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:266s:3583a
33. J Mendelsohn J Baselga 2000 The EGF receptor family as targets for cancer therapy Oncogene 19 6550 6565
34. AM Petit J Rak MC Hung 1997 Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors Am J Pathol 151 1523 1530
35. H Mellstedt 2003 Monoclonal antibodies in human cancer Drugs of Today 39 Suppl C 1 16
36. Khazaeli MB, LoBuglio AF, Falcey JW, Paulter VJ, Fetzer KM, Waksal HW. Low immunogenicity of a chimeric monoclonal antibody (MoAb), IMC-C225, used to treat epidermal growth factor recepto-positive tumors. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 20, 2000; New Orleans, Louisiana [Abstract 808]
37. D Schrag KY Chung C Flombaum L Saltz 2005 Cetuximab therapy and symptomatic hypomagnesemia J Natl Cancer Inst 97 1221 1224
38. Saltz L, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus Irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Paper presented at: American Society of Clinical Oncology Annual Meeting; May 12, 2001; San Francisco, California [Abstract 7]
39. Rosenberg AH, Loehrer P, Needle MN, et al. Erbitux (IMC-C255) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EFGr). Paper presented at: American Society of Clinical Oncology Annual Meeting; May 18, 2002; Orlando, Florida [Abstract 536].
40. Spitzer G, Zackon I, Stella P, Zehngebot L, Henderson C. Anti-epidermal growth factor (EGFR) antibody, cetuximab, in patients with stage IV colorectal carcinoma who failed all standard therapy: Final report of an access protocol. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings, 2005;23:282s:3646a
41. KA Foon XD Yang LM Weiner 2004 Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody Int J Radiat Oncol Biol Phys 58 984 990
42. Berlin J, Malik I, Picus J, et al. Panitumumab therapy with irinotecan, 5-fluorouracil, and leucovorin (IFL) in patients (pts) with metastatic colorectal cancer (mCRC). Ann Oncol 2004;15(Suppl 3):70
43. T Crombet M Osorio T Cruz 2004 Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients J Clin Oncol 22 1646 1654
44. Pfister D, Lipton A, Belt R, et al. A phase I trial of the epidermal growth factor receptor (EGFR)-directed bispecific antibody (BsAB) MDX-447 in patients with solid tumors. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 15, 1999; Atlanta, Georgia [Abstract 1667]
45. N Thatcher A Chang P Parikh 2005 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 1527 1537
46. CL Arteaga 2003 ErbB-targeted therapeutic approaches in human cancer Exp Cell Res 284 122 130
47. Bridgewater JA, Harrison M, Broby S, Currie C, Propper D. Phase I clinical trial of Gefitinib and 5FU in patients with 5FU-refractory colorectal cancer. Paper presented at: American Society of Clinical Oncology Annual Meeting Gastrointestinal Cancers Symposium; January 27, 2005; Miami, Florida [Abstract 292]
48. TD Barber B Vogelstein KW Kinzler VE Velculescu 2004 Somatic mutations of EGFR in colorectal cancers and glioblastomas N Engl J Med 351 2883
49. Delord JP, Beale P, Van Cutsem E, et al. A phase Ib dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2004;22:266s:3585a
50. Messersmith WA, Baker SD, Dinh K, et al. Phase I trial and biologic study of Erlotinib combined with FOLFOX-4 in patients with advanced colorectal cancer: initial results. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2004;22:208s:3052a
51. Versola M, Burris HA, Jones S, et al. Clinical activity of GW572016 in EGF10003 in patients with solid tumors. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2004;22:206s:3047a
52. Schwartz G, Chu SC, Hammond LA, et al. Phase I clinical, biology and pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2004;22:212s:3070a
53. Tejpar S, Van Cutsem E, Gamelin E, et al. Phase 1/2a study of EKB-569,an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC). J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2004;22:264s:3579a
54. Casado E, Folprecht G, Paz-Ares L, et al. A phase I/IIA pharmacokinetic (PK) and serial skin and tumor pharmacodynamic (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients (pts) with advanced colorectal cancer (ACC). J Clin Oncol, 2004 ASCO Annual Meeting Proceedings, 2004;22:255s:3543a
55. Nemunaitis JJ, Eiseman I, Cunningham C, et al. A phase 1 trial of CI-1033, a pan-erbB tyrosine kinase inhibitor, given daily for 14 days every 3 weeks, in patients with advanced solid tumors. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31, 2003; Chicago, Illinois